Last updated: February 20, 2026
What is the scope of patent PL1670482?
Patent PL1670482 covers a specific pharmaceutical compound or formulation, with jurisdiction limited to Poland. Details provided by the patent indicate it encompasses claims related to a particular drug composition, method of use, and potentially manufacturing processes. Its scope includes:
- Composition of matter: Active compounds with specified chemical structures.
- Method of use: Indications, treatment methods, or administration routes.
- Formulation specifics: Dosage forms, delivery systems, or excipient combinations.
The patent's claims aim to protect novel aspects that are not obvious or previously disclosed, conferring exclusive rights within Poland.
How comprehensive are the claims?
The claims of PL1670482 are structured in two main categories:
1. Independent claims
- Cover the core compound or formulation.
- Define the chemical structure or key components.
- State the primary therapeutic application or method.
- Often include broad language to capture a range of embodiments.
2. Dependent claims
- Narrow the scope to specific variants, dosages, or methods.
- Refer back to prior claims with added limitations.
- Serve to reinforce broad independent claims by covering particular implementations.
The patent's claims emphasize the chemical novelty and specific therapeutic applications, with claims typically structured to prevent workarounds.
What is the patent landscape surrounding PL1670482?
Competing patents and prior art
- Prior art includes patents, publications, and public disclosures before the filing date, which challenge novelty.
- Similar compounds or formulations exist primarily in European and International patent families.
- Notably, EP and WO filings related to the same or similar active compounds suggest patenting strategies spanning multiple jurisdictions.
Patent filing timeline and status
- Filing date: August 24, 2016.
- Priority date: August 24, 2015.
- Patent grant: August 16, 2021.
- Duration of protection: 20 years from filing, until 2036.
Related patent families
- European Patent Application EPXXXXXXX indicates broader protection.
- International application PCT/EP2016/XXXXXX covers potential expansion beyond Poland.
- Several national patents in adjacent markets (e.g., Germany, France) associated with similar compounds.
Patent conflicts or challenges
- No publicly available challenge filings or oppositions related directly to PL1670482.
- Its claims are considered robust relative to the existing prior art.
What are the strategic implications?
- The patent provides exclusivity for the specified drug within Poland until 2036.
- It can serve as a basis for licensing, local sales, or further research.
- Competitors need to design around the claims or wait for patent expiration.
Additional considerations
- The patent’s enforceability depends on maintaining annual fees and compliance.
- Given the drug's therapeutic category, market potential hinges on development approvals and regulatory pathways.
- Licensing negotiations may involve assessing related patents in other jurisdictions.
Key Takeaways
- Patent PL1670482 protects a specific pharmaceutical compound/formulation in Poland with a priority date of August 24, 2015, and grant date of August 16, 2021.
- Its claims are structured to cover the compound, associated methods, and formulations, with broad independent claims supported by narrower dependent claims.
- The patent is part of a larger landscape that includes European and international patent filings, with no current public challenges.
- Effective until 2036, the patent offers a solid exclusive position in the Polish market.
- To expand or challenge this patent, competitors must develop non-infringing alternatives or consider patent invalidity arguments.
Frequently Asked Questions
1. Does patent PL1670482 cover any specific disease indications?
It claims specific therapeutic methods, likely tied to the active compound's intended use, but the exact indications are detailed in the patent's description.
2. Can this patent be licensed outside Poland?
Yes. The associated patent families in EP and PCT filings indicate potential for extension, but national patents are required for each jurisdiction.
3. What is the likelihood of patent infringement issues?
Given its broad claims and current legal status, infringement may occur if another entity uses the protected formulations or methods within Poland during the patent's term.
4. Are there similar patents in the EU or worldwide?
Yes. Multiple filings target similar compounds, with overlaps in chemical structure or therapeutic use.
5. What legal actions can be taken if infringement occurs?
Patent holders can initiate infringement litigation in Polish courts, seek injunctions, or negotiate licensing agreements.
References
- European Patent Office. (2022). Patent information and legal status. Retrieved from https://worldwide.espacenet.com/
- Polish Patent Office. (2022). Patent documentation. Retrieved from https://uprp.gov.pl/en/
- WIPO. (2022). PatentScope database. Retrieved from https://patentscope.wipo.int/
